568.15MMarket Cap-15455P/E (TTM)
44.990High42.980Low51.30KVolume42.260Open42.260Pre Close2.25MTurnover0.86%Turnover RatioLossP/E (Static)12.98MShares53.00052wk High3.33P/B260.48MFloat Cap12.20052wk Low--Dividend TTM5.95MShs Float1115.000Historical High--Div YieldTTM4.76%Amplitude7.500Historical Low43.816Avg Price1Lot Size
Neurogene Stock Forum
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet